Search

Displaying results 2541 - 2550 of 7452 in total
  1. Drug

    Daclizumab

    go.drugbank.com/drugs/DB00111
    ApprovedInvestigationalWithdrawn

    On 22 April 2008, Roche Registration Limited chose to voluntarily withdraw the marketing authorization for their product Zenapax (daclizumab), as indicated for the prophylaxis of acute organ rejection … Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by

  2. Drug

    Fluspirilene

    go.drugbank.com/drugs/DB04842
    ApprovedWithdrawn

    A long-acting injectable antipsychotic agent used for chronic schizophrenia.

  3. Drug

    Isosorbide mononitrate

    go.drugbank.com/drugs/DB01020
    ApprovedInvestigational

    Like other organic nitrates, isosorbide mononitrate acts as a prodrug for its active metabolite, [nitric oxide], which mediates the therapeutic action of isosorbide mononitrate. … [T28] First approved by the FDA in 1991,[L11743] isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset of action of

  4. Drug

    Xylose

    go.drugbank.com/drugs/DB09419
    ApprovedWithdrawn

    The dextrorotary form of xylose, D-xylose, refers usually to the endogenously occurring form of the sugar in living things. The levorotary form, L-xylose, can refer to the form that is synthesized.

  5. Drug

    Glipizide

    go.drugbank.com/drugs/DB01067
    ApprovedInvestigational

    [L6712] Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed … [A179488] Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting

  6. Drug

    AT1391

    go.drugbank.com/drugs/DB05120
    Experimental

    AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.

  7. Drug

    Diazepam

    go.drugbank.com/drugs/DB00829
    ApprovedIllicitInvestigationalVet approved

    for complete, consistent drug absorption and rapid onset of effect [L5200]. … Combining diazepam, a proven effective therapy for acute repetitive seizures, with an auto-injector designed for subcutaneous administration that is quickly and easily administered offers the potential

  8. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). … The investigational drug was under investigation in clinical trial NCT00473928 (Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD) (ASaP)).

  9. Drug

    Bromfenac

    go.drugbank.com/drugs/DB00963
    ApprovedWithdrawn

    Bromfenac is a nonsteroidal anti-inflammatory drug (NSAID) for ophthalmic use. Ophthalmic NSAIDs are becoming a cornerstone for the management of ocular pain and inflammation. … Their well-characterized anti-inflammatory activity, analgesic property, and established safety record have also made NSAIDs an important tool for optimizing surgical outcomes.

  10. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    [L44096] In April 2026, the FDA approved an expanded indication for teplizumab, lowering the eligible age range from 8 years and older down to 1 year and older for patients with Stage 2 T1D.[L56140]